Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.

ABSTRACT:

Background

Rapid improvements in hepatitis C virus (HCV) therapy have led to the approval of multiple oral direct-acting antiviral (DAA) regimens by the U.S. Food and Drug Administration (FDA) for treatment of chronic HCV infection.

Purpose

To summarize published literature on the efficacy and safety of oral DAAs for treatment of persons with chronic HCV infection.

Data sources

MEDLINE and EMBASE from inception through 1 November 2016.

Study selection

42 English-language studies from controlled and single-group registered clinical trials of adults with HCV infection that evaluated at least 8 weeks of an FDA-approved interferon-free HCV regimen that included at least 2 DAAs.

Data extraction

Two investigators abstracted data on study design, patient charac

SUBMITTER: Falade-Nwulia O 

PROVIDER: S-EPMC5486987 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature